74%
de los inversores minoristas pierde dinero cuando opera CFDs con este proveedor.
Invertir conlleva riesgos y no es adecuado para todos los inversores. Los CFDs son instrumentos complejos y conllevan un alto riesgo de perder dinero rápidamente debido al apalancamiento.
74%
de inversores minoristas pierde dinero al operar CFDs con este proveedor.
Debes considerar si entiendes cómo funcionan los CFDs y si puedes permitirte asumir el alto riesgo de perder tu dinero.
74%
de los inversores minoristas pierde dinero cuando opera CFDs con este proveedor.
Invertir conlleva riesgos y no es adecuado para todos los inversores. Los CFDs son instrumentos complejos y conllevan un alto riesgo de perder dinero rápidamente debido al apalancamiento.
74%
de inversores minoristas pierde dinero al operar CFDs con este proveedor.
Debes considerar si entiendes cómo funcionan los CFDs y si puedes permitirte asumir el alto riesgo de perder tu dinero.
Camurus AB
Cerrado
723.5 -0.07
Resumen
Variación precio
24h
Mínimo
716
Máximo
730
Ingresos | 53M 292M |
|---|---|
Ventas | 117M 676M |
P/B Media del Sector | 59.883 35.733 |
BPA | 4.08 |
Margen de beneficios | 43.235 |
Empleados | 267 |
EBITDA | 54M 315M |
Capitalización Mercado | 1.8B 43B |
|---|---|
Apertura anterior | 723.57 |
Cierre anterior | 723.5 |
Camurus AB Gráfico
Resultados pasados no son un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
Camurus AB previsión
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$
Acerca de Camurus AB
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain and Brixadi to treat opioid use disorder. Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; and Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity, as well as licensing agreement with Solasia Pharma. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.
Otras acciones del sector
Live chat